Aurora-A和EGFR联合表达与肺腺癌侵袭转移的相关性研究

目的探讨Aur-A和表皮生长因子受体(EGFR)在肺腺癌组织中的表达及其与临床病理特征的关系。方法用免疫组化方法检测105例肺腺癌组织中Aur-A与EGFR的表达,并与临床病理因素进行相关性分析。结果 Aur-A在肺腺癌组织中的阳性率为71.4%(75/105)。Aur-A与EGFR表达呈正相关(r=0.416,P0.05),Aur-A的表达与临床分期、淋巴结转移相关(P0.05),Aur-A与EGFR的共表达与淋巴结转移有关(P0.05)。结论 Aur-A阳性表达可作为评价肺腺癌发生发展的生物学指标,联合EGFR检测更有助于肺腺癌侵袭转移的判断。

The expression correlation of Aurora-A and EGFR in lung adenocarcinoma

Objective This study was designed to investigate the expression of Aurora-A （Aur-A） and epidermal growth factor receptor （EGFR）, and the clinicopathological significance of Aur-A and EGFR in patients with resected lung adenocarcinoma. Methods The protein expression of Aur-A and EGFR in 105 lung adenocarcinoma tissues were assessed by Immunohistochemistry （IHC）, and their correlations with clinicopathological features were statistically analyzed. Results The over-expression rate of Aur-A was 71.4% （75/105）. A positive correlation between Aur-A over-expression rate and ascending pathological stages was observed （P〈0.05）. In addition, the expression of Aur-A had a positive correlation with EGFR （P〈0.001）. The co-expression of Aur-A and EGFR related to node metastasis status （P〈0.05）. Conclusion The expression of Aur-A could be considered as a biological marker to estimate the progression of lung adenocarcinoma. Combine detection of EGFR may help to judge the metastasis of lung adenocarcinoma.